Loading...
Please wait, while we are loading the content...
Similar Documents
Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
| Content Provider | MDPI |
|---|---|
| Author | David, Ramírez Javier, García-Cárceles Ginex, Tiziana Garaigorta, Urtzi Castro, Victoria Nozal, Vanesa Maestro, Inés Campillo, Nuria Martinez, Ana Gastaminza, Pablo Gil, Carmen |
| Copyright Year | 2021 |
| Description | The unprecedent situation generated by the COVID-19 global emergency has prompted us to actively work to fight against this pandemic by searching for repurposable agents among FDA approved drugs to shed light into immediate opportunities for the treatment of COVID-19 patients. In the attempt to proceed toward a proper rationalization of the search for new antivirals among approved drugs, we carried out a hierarchical in silico/in vitro protocol which successfully combines virtual and biological screening to speed up the identification of host-directed therapies against COVID-19 in an effective way. To this end a multi-target virtual screening approach focused on host-based targets related to viral entry, followed by the experimental evaluation of the antiviral activity of selected compounds, has been carried out. As a result, five different potentially repurposable drugs interfering with viral entry—cepharantine, clofazimine, metergoline, imatinib and efloxate—have been identified. |
| Starting Page | 332 |
| e-ISSN | 14248247 |
| DOI | 10.3390/ph14040332 |
| Journal | Pharmaceuticals |
| Issue Number | 4 |
| Volume Number | 14 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-04-06 |
| Access Restriction | Open |
| Subject Keyword | Pharmaceuticals Medicinal Chemistry Sars-cov-2 Evaluation Covid-19 Drug Repurposing Host-based Targets Virtual Screening Entry Inhibitors |
| Content Type | Text |
| Resource Type | Article |
